These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30965327)

  • 1. Osteolytic Lesions in Primary Myelofibrosis and Effect of Ruxolitinib Therapy: Report of a Case and Literature Review.
    Bucelli C; Cattaneo D; Valli VB; Levati GV; Lonati S; Gianelli U; Iurlo A
    Chemotherapy; 2018; 63(6):340-344. PubMed ID: 30965327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.
    Chen YY; Huang CE; Lee KD; Chen CC
    Hematology; 2016 Jan; 21(1):3-9. PubMed ID: 26214121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
    Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
    N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
    Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis.
    Del Rosario M; Tsai H; Dasanu CA
    J Oncol Pharm Pract; 2018 Apr; 24(3):226-228. PubMed ID: 28436280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ruxolitinib.
    Becker H; Engelhardt M; von Bubnoff N; Wäsch R
    Recent Results Cancer Res; 2014; 201():249-57. PubMed ID: 24756798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.
    Kvasnicka HM; Thiele J; Bueso-Ramos CE; Sun W; Cortes J; Kantarjian HM; Verstovsek S
    J Hematol Oncol; 2018 Mar; 11(1):42. PubMed ID: 29544547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?
    Breccia M; Molica M; Colafigli G; Alimena G
    Expert Rev Hematol; 2015 Aug; 8(4):387-9. PubMed ID: 25915176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
    Al-Ali HK; Griesshammer M; Foltz L; Palumbo GA; Martino B; Palandri F; Liberati AM; le Coutre P; García-Hernández C; Zaritskey A; Tavares R; Gupta V; Raanani P; Giraldo P; Hänel M; Damiani D; Sacha T; Bouard C; Paley C; Tiwari R; Mannelli F; Vannucchi AM
    Br J Haematol; 2020 Jun; 189(5):888-903. PubMed ID: 32017044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation.
    Beauverd Y; Samii K
    Int J Hematol; 2014 Nov; 100(5):498-501. PubMed ID: 25034748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
    Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
    Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib.
    Wilkins BS; Radia D; Woodley C; Farhi SE; Keohane C; Harrison CN
    Haematologica; 2013 Dec; 98(12):1872-6. PubMed ID: 24056820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report.
    Aylı M; Özcan M; Cengiz Seval G
    Turk J Haematol; 2015 Jun; 32(2):180-3. PubMed ID: 26316489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
    Arana Yi C; Tam CS; Verstovsek S
    Future Oncol; 2015; 11(5):719-33. PubMed ID: 25757677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
    Bryan JC; Verstovsek S
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of bone marrow microenvironment following ruxolitinib therapy in myelofibrosis.
    Caocci G; Maccioni A; Murgia F; Perra A; Usai M; Piga M; Mascia R; La Nasa G
    Leuk Lymphoma; 2016 May; 57(5):1215-8. PubMed ID: 26308187
    [No Abstract]   [Full Text] [Related]  

  • 17. JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.
    Evrot E; Ebel N; Romanet V; Roelli C; Andraos R; Qian Z; Dölemeyer A; Dammassa E; Sterker D; Cozens R; Hofmann F; Murakami M; Baffert F; Radimerski T
    Clin Cancer Res; 2013 Nov; 19(22):6230-41. PubMed ID: 24081976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence.
    Harrison CN; Talpaz M; Mead AJ
    Leuk Lymphoma; 2016 Oct; 57(10):2259-67. PubMed ID: 27463690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolated Nodal TBC Reactivation in a Patient with Post-Thrombocythemia Myelofibrosis Treated with Ruxolitinib: Case Report and Review of the Literature.
    Santoro M; Rotolo C; Accurso V; Morreale I; Mancuso S; Siragusa S
    Chemotherapy; 2021; 66(3):87-91. PubMed ID: 33784668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberculosis reactivation related with ruxolitinib in a patient with primary myelofibrosis.
    Pepeler MS; Özkurt ZN; Güzel ÖT; Akyürek N
    J Infect Dev Ctries; 2018 Oct; 12(10):926-928. PubMed ID: 32004164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.